Pulmonx Corp
(FRA:4NI)
€
1.76
+0.080 (+4.79%)
Market Cap: 85.11 Mil
Enterprise Value: 85.43 Mil
PE Ratio: 0
PB Ratio: 2.51
GF Score: 62/100 Pulmonx Corp at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2022 / 08:40PM GMT
Release Date Price:
€20
(+4.17%)
Cecilia E. Furlong
Morgan Stanley, Research Division - Equity Analyst
Good afternoon, and welcome to the second day -- nearly the end of the second day of the Morgan Stanley Healthcare Conference. I am Cecilia Furlong, medical device analyst here at Morgan Stanley. It is my pleasure to have Pulmonx with us; CEO, Glen French; CFO, Derrick Sung. Thank you both for being here today.
Glendon E. French
Pulmonx Corporation - CEO, President & Director
Thank you.
Questions & Answers
Cecilia E. Furlong
Morgan Stanley, Research Division - Equity Analyst
And I think we've started a lot of these conversations with macro. I'd love to start with CONVERT given what we've heard recently from a data standpoint. But as you think about just for the field? What's the greatest potential benefit as you contemplate further adoption?
Glendon E. French;Cecilia E. Furlong
Pulmonx Corporation - CEO, President & Director
Specific to CONVERT or...
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot